A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS One, 7, e41936. presented at the 08/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22870265. (2012).
Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE, 5, e12873. presented at the 09/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20877623. (2010).
Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA-and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes. J Virol, 80, 4717-4728. presented at the 05/2006. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16641265. (2006).
Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).
Trial-related discrimination in HIV vaccine clinical trials. AIDS Res HumRetroviruses, 17, 667-74. presented at the 2001.. (2001).
Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses, 17(8), 667-74. presented at the 2001 May 20. doi:10.1089/088922201750236942. (2001).